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Abstract
Introduction—The PhenX Toolkit, an online resource of well-established measures of 
phenotypes and exposures, now has 16 new measures recommended for assessing rare genetic 
conditions.
Materials and Methods—These measures and their protocols were selected by a working 
group of domain experts with input from the scientific community.
Results—The measures cover life stages from birth through adulthood, and include clinical 
scales, characterization of rare genetic conditions, bioassays, and questionnaires. Most are broadly 
applicable to rare genetic conditions, e.g., family history, growth charts, bone age, and body 
proportions. Some protocols, e.g., sweat chloride test, target specific conditions.
Discussion—The rare genetic condition measures complement the existing measures in the 
PhenX Toolkit that cover anthropometrics, demographics, mental health, and reproductive history. 
They are directed at research pertaining to common and complex diseases. PhenX measures are 
publicly available and are recommended to help standardize assessments across a range of 
biomedical study designs. To facilitate incorporation of measures into human subjects’ research, 
the Toolkit offers data collection worksheets, and compatible data dictionaries.
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
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Conclusion—Widespread use of standard, PhenX measures in clinical, translational and 
epidemiological research will enable more uniform cross-study comparisons and increase 
statistical power with the potential for enhancing scientific discovery.
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INTRODUCTION
PhenX uses a consensus-based process to identify measures of phenotypes and exposures for 
biomedical studies. Funded by the National Human Genome Research Institute (NHGRI) 
and the National Institute on Drug Abuse (NIDA), with supplemental funding from other 
NIH institutes for specific research areas or conditions (e.g. mental health, sickle cell 
disease, tobacco regulatory research, and substance use), the PhenX Toolkit is a web-based 
catalog which includes more than 450 measures which broadly addresses 23 research 
domains and adds depth in four research areas. As of May 5, 2016, the PhenX Toolkit has 
been recommended in 166 NIH funding opportunity announcements. Measures in the PhenX 
Toolkit are publicly available at www.phenxtoolkit.org.
Originally, when the PhenX Toolkit was made available in 2008, it was a resource mainly 
for genome-wide association studies (GWAs) but with the addition of research domains and 
more specific disciplines it expanded to epidemiological and biomedical research. The 
PhenX Toolkit is ideal for investigators who want to expand their disease-specific studies 
into other disciplines that are outside the focus of their research. This gives investigators 
without expertise in these disciplines an opportunity to incorporate high quality measures 
into their studies at the study design stage (Hamilton et al., 2011).
The PhenX Steering Committee (SC), which consists of 10 researchers who were 
recommended because of their broad genetic, epidemiology and biomedical research 
expertise, provides guidance to the project (Maiese et al., 2013). In 2013, the SC decided 
that the field of genetics would benefit from a set of standard measures to encourage 
research in rare (very low prevalence) diseases and syndromes (De La Paz et al., 2010). This 
paper describes the process to select the measures in the Rare Genetic Conditions domain, 
details the measures selected for inclusion in the PhenX Toolkit, and describes the 
challenges in identifying these measures. Investigators are encouraged to utilize this 
carefully selected set of standard measures in a wide variety of study designs.
METHODS
The PhenX Rare Genetic Conditions Working Group (WG) consisted of medical and clinical 
geneticists, including three physicians, a pediatrician, a certified genetic counselor, an 
epidemiologist, a registered nurse, a patient advocate, and was supported by an SC liaison 
and staff from RTI International. The WG was charged with identifying up to 15 high 
priority measures to assess rare genetic conditions, the scope of which included organ 
systems, family health history, and genetic mutations. The WG used the definition of a rare 
disease enacted by the Orphan Drug Act of 1983 (a prevalence of fewer than 200,000 
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affected individuals in the United States), and focused on rare conditions that have a known 
genetic component (Orphan Drug Act, 1984).
Each WG member was assigned with one or more scope elements and reviewed existing 
relevant Toolkit measures and protocols, appropriate literature and current clinical and 
research tools used for data collection to recommend measures and protocols to vet with the 
WG. Most of the WG review occurred during a one day in-person meeting and additional 
discussion was held via multiple teleconferences. All of this occurred during an eight-month 
time period during 2014–15, and resulted in the WG coming to a consensus on 16 measures 
after identifying and vetting a total of 51 measures. The WG used the SC criteria (e.g., 
clearly defined, well-established, reproducible, low burden, used in a major study) for this 
selection and were mindful of the need to complement existing PhenX Toolkit content.
RESULTS
Sixteen new measures (see Table 1) were added to the PhenX Toolkit in April 2015 (see 
https://www.phenxtoolkit.org/index.php?pageLink=browse.measures&id=220000). Most 
measures (e.g., family history, growth charts, bone age and body proportions) are broadly 
applicable to rare genetic conditions research. Measures were not identified and 
subsequently recommended for each organ system because standardized protocols are not 
available (e.g., skin conditions) or tools for those phenotypes were already covered by 
existing Toolkit measures (e.g., ocular). Ideally, PhenX measures include nonproprietary 
protocols but two proprietary protocols (Disability Index, Scale of Developmental Domains 
of Early Childhood) were included in this domain because they were the most commonly 
used. Due to the complexity of assessing rare genetic condition phenotypes, nine of these are 
considered high burden measures (e.g., two require specialized training; two take more than 
15 minutes to administer to an unaffected individual; and five have both training and greater 
time requirements). Details about the burden appear in the Requirements section for each 
protocol.
Guidelines from the Human Genome Variation Society (HGVS), used to properly name 
genetic variants, was added as Supplemental Information (SI) as an additional resource for 
researchers. While highly relevant to rare genetic condition research, the guidelines were not 
a standardized protocol and did not meet the SC selection criteria for inclusion in the 
Toolkit.
To illustrate the content of the Toolkit, three of the rare genetic condition (RGC) measures 
are described below:
Family Health History
A multi-generational pedigree is the gold standard for family health history. Many pedigrees 
are proprietary instruments. The WG selected the U.S. Surgeon General’s web-based tool, 
My Family Health Portrait (MFHP, 2015). It is nonproprietary, customizable and captures 
the individual’s family health history through structured and open-ended questions. My 
Family Health Portrait is widely used; the website was accessed more than 1.7 million times 
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between 2011 and September 2015 (Sima Pandya, personal communication, October 27, 
2015).
Growth Charts
Abnormal growth is a feature of many rare genetic conditions, including Turner syndrome, 
Marfan syndrome, Noonan syndrome, and various forms of skeletal dysplasia. Growth 
charts provide information regarding deviations from typical growth patterns. This 
information along with other clinical and laboratory findings can assist investigators with 
their research. The World Health Organization (WHO) and the Centers for Disease Control 
and Prevention (CDC) growth charts were selected for the Growth Charts measure because 
they are the most common standard method used in clinical and research practice to record 
growth (CDC 2010, WHO 2016).
Ataxia Rating Scale
Ataxia is a symptom of several rare neurologic conditions, such as ataxia telangiectasia and 
the various forms of spinocerebellar ataxia (SCA). Disorders that affect the cerebellum cause 
most genetic forms of ataxia; hence, there are ataxia rating scales used to assess the severity 
of cerebellar ataxia. The Scale for the Assessment and Rating of Ataxia (SARA) was 
selected because it has good metric properties and inter-rater reliability, and is easily 
administered (Schmitz-Hübsch et al., 2006). The validation procedures for the SARA 
involved three large multi-center trials including patients with SCA and non-SCA ataxia, as 
well as controls. The SARA has been shown to be a reliable and valid scale for measuring 
ataxia, with scores that correlate closely with other scales of ataxia, as well as activities of 
daily living.
DISCUSSION
Clinicians and researchers may strongly wish to consider incorporating PhenX measures into 
their own practice and research efforts because meta-analyses with the standardized 
measures could lead to genetic discoveries. Since the PhenX Toolkit resource facilitates 
cross-study analyses the measures should be of particular interest to rare condition 
researchers because of the limited sample size in each trial or study. In addition, these 
approaches may expand the existing understanding of some genetic conditions and may lead 
to improved services and the health of those with these conditions.
The rare genetic condition measures can be accessed by users with varying levels of 
experience with rare genetic conditions. For instance, protocols are applicable to study 
designs that include individuals who have already been diagnosed, are being evaluated, or 
both. As a result, they are beneficial to researchers with experience with a specific rare 
condition, such as cystic fibrosis, as well as researchers who work with diseases for which a 
diagnosis is elusive.
Along with the research benefits to investigators from the rare genetic condition measures, 
there are limitations. For instance, the WG could not identify standard low-burden measures 
for certain organ or sensory systems, such as gastrointestinal, ocular, and auditory. Another 
challenge was to identify a standard measure for newborn screening (NBS). While each state 
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conducts NBS, the conditions for which each state screens vary, as do their cut offs for what 
constitutes disease. As a result, there was no WG consensus on a measure for NBS, so it was 
not included in the Toolkit. Similarly, no standard screening panel for rare metabolic genetic 
conditions was identified. Instead, health care providers order laboratory tests based upon an 
individual’s clinical evaluation and family history. Therefore, the WG did not include a 
measure for a metabolic screening panel.
In addition to the measures in the Rare Genetics Conditions Domain, there are other 
measures and resources in the Toolkit that are relevant to research in both common and rare 
genetic conditions. A collection of measures for sickle cell disease research was added to the 
Toolkit in July 2015. In addition, the Genetic Alliance (www.geneticalliance.org) led a 
crowdsourcing effort to annotate PhenX measures for specific genetic conditions. 
Researchers are encouraged to use this tool to annotate protocols for other rare genetic 
conditions. For example, the Exercise Capacity/Six-minute Walk Test is used to measure the 
response to medical interventions in patients with moderate to severe heart or lung disease; it 
is used as an outcome measure in people with Duchenne muscular dystrophy (McDonald et 
al., 2013). The annotation tool is available in the Resources tab of the PhenX Toolkit.
The PhenX Toolkit has several features which make it a user friendly resource. Investigators 
can use the search function to find measures of interest and then add them to their 
personalized Toolkit to be downloaded as needed. In addition to the measures, data 
collection worksheets and data dictionaries are available for each measure, which can be 
easily downloaded via a “My Toolkit” feature that functions similarly to an online retailer’s 
shopping cart. Investigators who become registered users of the PhenX Toolkit may save 
their work, share measures with colleagues, and receive updates about changes to the 
Toolkit. PhenX protocols are now available as “instrument zip” files on the Research 
Electronic Data Capture (REDCap) Shared Library Website making it easy for investigators 
to include PhenX measures into REDCap study designs (REDCap).
CONCLUSION
Rare genetic condition researchers are encouraged to use the PhenX Toolkit when designing 
studies or adding measures to their research protocols. The use of standard measures 
facilitates cross-study analysis with limited sample sizes. The PhenX Toolkit gives 
investigators the capacity to expand original research and to look at common risk factors and 
overlapping phenotypes across rare genetic conditions and common and complex diseases.
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Table 1
PhenX Measures in the Rare Genetic Conditions Domain (all of the measures are available by going to the 
following website and then opening the measure of interest https://www.phenxtoolkit.org/index.php?
pageLink=browse.measures&id=220000)
Measure Name Protocol Source Description of Measurement Protocol
Ataxia Rating Scale* Scale for the Assessment and 
Rating of Ataxia (SARA)
The SARA is a clinical scale used to assess cerebellar ataxia. The 
scale includes eight items that are related to gait, stance, sitting, 
speech, finger-chase test, nose-finger test, fast alternating 
movements, and heel-shin test.
Body Proportions Lifshitz, F. (Ed.). (2007); 
Lohman, T. G., et al (Eds.). 
(1988);
National Health and Nutrition 
Examination Survey (NHANES) 
2007–2008 and NHANES III: 
Body measurements 
(anthropometry)
Arm span–to-height comparison is determined by measuring the 
individual’s arm span and standing height and then comparing the 
two measurements (e.g., arm span is 3 centimeters greater than 
height).
Bone Age* Tanner and Whitehouse Method The latest Tanner and Whitehouse Method, sometimes referred to 
as TW2, involves the interpretation of a radiograph of the left 
hand and wrist by a trained radiologist.
Child Oral Health Pain Child Oral Health Impact 
Profile–Short Form 19 (COHIP-
SF 19)
The COHIP-SF 19 is a 19-item, interviewer-administered 
questionnaire about the oral health of a child to assess the child’s 
quality of life.
Complete Blood Count (CBC) NHANES 2010 The Complete Blood Count (CBC) protocol is a standard blood 
panel from the NHANES and is performed on participants ages 1 
and older.
Disability Index The Oswestry Disability Index 
(ODI©)
The ODI version 2.1a is a 10-item, proprietary, self-administered 
questionnaire that asks questions regarding how an individual’s 
back (or leg) trouble affects the ability to perform routine daily 
activities.
Disease Progression and 
Regression*
Newcastle Paediatric 
Mitochondrial Disease Scale 
(NPMDS) and Newcastle 
Mitochondrial Disease Adult 
Scale (NMDAS)
The NPMDS and the NMDAS can be used to evaluate the 
progression of mitochondrial disease. There are three versions of 
the NPMDS, each for a specific age range (0–24 months, 2–11 
years, and 12–18 years). The NMDAS is for adult patients over 16 
years.
Disorders of Respiratory Control 
with Inherent Autonomic 
Dysregulation*
Weese-Mayer, D. E., et al. 2010 The American Thoracic Society (ATS) policy statement regarding 
Congenital Central Hypoventilation Syndrome (CCHS) is a 
comprehensive guide for diagnosing an individual with CCHS by 
evaluating his or her phenotype and determining their paired-like 
homeobox gene (PHOX2B) genotype.
Echocardiography Phenotypes* The British Society of 
Echocardiography (BSE) web 
site
The BSE Education Committee guidelines for a standard 
transthoracic echocardiogram (TTE) consist of a minimum data 
set and a recommended sequence on how to perform a 
comprehensive assessment.
Family Health History My Family Health Portrait 
(MFHP)
MFHP is a free, Internet-based tool that allows individuals to 
record their family health history (in the form of a pedigree) and 
that is used to collect information regarding the individual and his 
or her close biological relatives.
Growth Charts The World Health Organization 
(WHO) and Centers for Disease 
Control and Prevention (CDC) 
websites
WHO and CDC growth charts include standard graph lines and a 
series of percentile curves that demonstrate the distribution of 
certain body measurements.
Quality of Life PROMIS® 25 Profile - v.1.1 Pediatric: PROMIS® Profile 25 consists of seven item banks: 
physical function mobility, anxiety, depressive symptoms, fatigue, 
peer relationships, pain interference, and pain intensity.
PROMIS®-29 Profile v2.0 Adult 
Profile©.
Adult: This protocol includes 29 self-administered, quality-of-life-
type questions from the PROMIS® Profile 29 for adults. The 
quality-of-life questions include physical function, anxiety, 
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Measure Name Protocol Source Description of Measurement Protocol
depression, fatigue, sleep disturbance, ability to participate in 
social roles and activities, and pain intensity.
Scale of Developmental Domains of 
Early Childhood*
The Mullen Scales of Early 
Learning
The Mullen Scales of Early Learning includes five scales that 
provide information on an infant’s or child’s cognitive and motor 
ability and also assess a child’s readiness for school.
Scoliosis – Physical Assessment* Adam’s forward bend test, X-
ray, Cobb technique
The aggregate protocol includes the Adam’s forward bend test and 
an x-ray with Cobb technique to determine if an individual has 
scoliosis.
Scoliosis – Quality of Life* Pediatric Outcomes Data 
Collection Instrument (PODCI)
The PODCI consists of 86 items and is designed to collect data 
regarding an individual’s general health and problems related to 
bone and muscle conditions.
Sweat Chloride Test* Clinical and Laboratory 
Standards Institute, 2009;
LeGrys, V. A., et al., (2007)
Quantitative pilocarpine iontophoresis is the procedure also 
known as the sweat chloride test.
Genetic Variant Nomenclature 
Standards (in Supplemental 
Information) **
The Human Genome Variation 
Society (HGVS) guidelines for 
sequence variant nomenclature
Wildeman, M. et al., (2008)
The HGVS guidelines for sequence variant nomenclature is a 
comprehensive guide on how to describe (i.e., name) any 
identified variant by a standardized method. Mutalyzer is a free 
online tool which is primarily used to check that sequence variant 
descriptions follow the HGVS nomenclature guidelines.
*
High burden measure.
**Supplemental Information describes the scope of each PhenX Domain or Collection, includes other measure(s) considered by the Working 
Group (not selected for the Toolkit) and additional comments from the Working Group.
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